Stryker Corporation $SYK Stake Trimmed by K.J. Harrison & Partners Inc

K.J. Harrison & Partners Inc cut its position in shares of Stryker Corporation (NYSE:SYK) by 86.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,815 shares of the medical technology company’s stock after selling 11,670 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in Stryker were worth $596,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. VanderPol Investments L.L.C. raised its holdings in shares of Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after acquiring an additional 28 shares during the period. KCM Investment Advisors LLC boosted its stake in Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC grew its position in Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC grew its position in Stryker by 2.7% during the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares in the last quarter. Finally, Mechanics Financial Corp raised its stake in Stryker by 1.2% during the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock valued at $864,000 after purchasing an additional 30 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of NYSE SYK opened at $326.41 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The business’s 50-day moving average price is $309.80 and its two-hundred day moving average price is $338.75. The company has a market capitalization of $125.13 billion, a P/E ratio of 37.78, a price-to-earnings-growth ratio of 2.09 and a beta of 0.77.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period last year, the business earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Analyst Ratings Changes

Several analysts have recently commented on the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research report on Friday, May 1st. Robert W. Baird set a $385.00 price target on Stryker in a research report on Friday, May 1st. Weiss Ratings downgraded Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Leerink Partners decreased their price objective on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, BTIG Research lowered their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $395.33.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the sale, the director directly owned 1,924,880 shares in the company, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 323,264 shares of company stock worth $100,659,489 in the last 90 days. 4.60% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.